ModifiedUnitedHealthcarePolicy CS334IN.08

Prostate Surgeries and Interventions (for Indiana Only)

Defines UnitedHealthcare medical policy for prostate surgical and interventional procedures applicable to members in Indiana, describing which procedures are considered medically necessary or unproven/not medically necessary and referencing InterQual criteria where applicable.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Indiana Only)

Policy CodePolicy CS334IN.08

Change TypePolicy revision effective 04/01/2026 with material coverage updates

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionInclude legible medical record documentation (history, exam, diagnostics, trial eligibility data) to support medical necessity and prior authorization requests.

SourceLink

POLICY UPDATE CHANGES

Removed coverage guidelines for transperineal placement of biodegradable material.

Replaced general language to specify cryoablation is medically necessary for recurrent prostate cancer diagnosed by biopsy and is unproven/not medically necessary for initial treatment and other indications.

Changed transurethral water jet ablation wording to state it is proven and medically necessary for resection/removal of prostate tissue for LUTS due to BPH and unproven/not medically necessary for malignant prostate tissue and other indications.

Added requirements clarifying that medical records must fully support medical necessity and may be required for review.

Indiana-onlypolicy jurisdiction

1 RCT (Aquablation vs TURP)key RCT evidence

variable

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

insufficient long-term dataPAE evidence gap

04/01/2026revision date

Coverage Criteria and Policy Stance

inv-01: Transurethral ablation — stance and routing to InterQual

Covered when criteria met; refer to InterQual for clinical specifics.

Transurethral ablation: Proven and medically necessary in certain circumstances; for medical necessity clinical coverage criteria refer to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Unproven and not medically necessary for all other indications.

inv-02: Cryoablation — recurrent cancer only

Covered only for recurrent prostate cancer diagnosed by biopsy; other uses unproven.

Cryoablation for recurrent cancer: Medically necessary for recurrent prostate cancer diagnosed by biopsy; for clinical coverage criteria refer to InterQual CP: Procedures, Cryoablation, Prostate.

Unproven and not medically necessary for initial treatment of prostate cancer and other indications due to insufficient evidence of safety/efficacy.

Evidence summary: Systematic reviews report heterogeneous observational studies with no RCTs for primary cryoablation and limited comparative data; oncologic outcomes and reporting are inconsistent, supporting restriction to recurrent biopsy‑proven disease.

inv-03: Prostatic urethral lift — FDA labeled indications

Covered when performed within the FDA-labeled indications and contraindications.

PUL (UroLift) — FDA labeled indications: Indicated for men ≥45 years with urinary outflow obstruction secondary to BPH (lateral lobes, with or without median lobe); prostate volume must be ≤100 cc; no urinary tract infection; no urethral conditions preventing insertion of the delivery system into the bladder; no urinary incontinence due to an incompetent sphincter; and no current gross hematuria.prostate volume ≤ 100 cc

PUL is unproven and not medically necessary for all other indications due to insufficient evidence.

inv-04: Water vapor and water jet ablation — BPH indications

Coverage differs by modality and indication.

High-energy water vapor thermotherapy (Rezūm): Proven and medically necessary in certain circumstances; for medical necessity clinical coverage criteria refer to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Treatment of malignant prostate tissue and all other indications is unproven and not medically necessary.

Transurethral water jet ablation (Aquablation): Proven and medically necessary for resection and removal of prostate tissue to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia; treatment of malignant prostate tissue and all other indications is unproven and not medically necessary.

Randomized trials versus TURP support similar medium‑term efficacy and ejaculatory preservation in selected patients.

inv-05: Prostate artery embolization — restricted indications

PAE may be medically necessary for restricted patient groups; not covered for other indications.

PAE — restricted indications: Proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (comorbidities), or for persistent gross hematuria originating from the prostate.

Unproven and not medically necessary for all other indications due to insufficient evidence.

PAE evidence considerations: Randomized trials and systematic reviews show short‑term perioperative benefits versus TURP (less blood loss, shorter hospitalization) but generally less improvement in functional parameters and higher retreatment rates; overall certainty is low to moderate, supporting use primarily when standard surgical options are unsuitable.

Prior authorization recommended to document failed conservative therapy or contraindication to standard surgery.

inv-06: Unproven / not medically necessary procedures

These procedures lack sufficient evidence for routine coverage.

Unproven procedures list: The following are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy: transperineal focal laser ablation; insertion of a temporary prostatic urethral stent; transperineal laser ablation (TPLA); ablation of malignant prostate tissue by magnetic field induction; transurethral drug‑coated balloon dilation (Optilume) when used outside studied indications; and transurethral thermal ultrasound ablation (TULSA).

Many of these are appropriate only within clinical trials or prospective comparative studies.

inv-07: Coverage-relevant evidence summaries

Key evidence conclusions that affect coverage decisions.

Aquablation evidence: RCT evidence (Gilling et al.) shows aquablation and TURP have similar IPSS and Qmax improvements up to 2–5 years, with potential ejaculatory preservation advantages for aquablation; supports consideration as an alternative in selected patients.RCT follow‑up up to 5 years

PUL evidence: Randomized trials including a sham‑controlled study demonstrate durable symptom improvement up to 5 years with PUL, though peak flow improvements are inferior to TURP; appropriate for patients matching trial eligibility.trial inclusion examples (e.g., IPSS >12, prostate 30–80 cc)

Cryoablation evidence: Systematic reviews report heterogeneous observational evidence with limited randomized data and inconsistent oncologic reporting; primary cryoablation lacks high‑quality comparative evidence, supporting restriction to recurrent biopsy‑proven disease.

inv-08: PAE — efficacy and limitations

Synthesis of clinical trial and systematic review findings relevant to PAE.

PAE efficacy and limitations: Randomized trials and systematic reviews indicate PAE can improve patient‑reported symptoms short‑term and may have fewer immediate adverse events and shorter hospital stays compared with TURP, but PAE generally yields less improvement in objective functional parameters (Qmax, prostate volume, PSA) and has higher retreatment rates up to 2 years; overall certainty of evidence is low to moderate.

Consider PAE primarily for patients unsuitable for standard surgery; prior authorization recommended.

inv-09: PAE — reported candidate populations

Contexts in which PAE has been studied and may be considered.

Reported candidate populations for PAE: Reported candidate groups include patients who are poor surgical candidates due to frailty or comorbidities, patients with large prostate volume in some studies, and patients with refractory gross hematuria originating from the prostate; evidence derives largely from case series, cohort studies, and some RCTs.

Documentation should show ineligibility for standard procedures when used for these indications.

inv-10: Transperineal focal laser ablation — efficacy and recommendations

Focal laser ablation evidence is limited and oncologic outcomes are uncertain; restrict use.

TPLA/FLA evidence synthesis: Available literature is limited to pilot studies, small series, and low‑quality comparative analyses; oncologic outcomes are conflicting with short follow‑up and some comparative data suggesting worse overall survival for FLA versus standard therapies; expert consensus recommends restricting FLA to clinical trials or prospective studies.

Not appropriate for routine care outside trials.

inv-11: Transperineal Laser Ablation (TPLA) — evidence summary

RCTs show tradeoffs between efficacy and sexual function for transperineal laser approaches.

TPLA evidence summary: Two randomized trials showed TPLA is inferior to TURP for urologic effectiveness but superior for preservation of sexual/ejaculatory function; evidence is limited by small sample sizes and short follow‑up, supporting restrictive coverage or use within trials.RCT evidence shows inferior efficacy

inv-12: Transperineal Focal Laser Ablation (FLA)

Focal laser ablation may be considered only in very selected patients and ideally within trials.

FLA candidate considerations: FLA may be considered only for carefully selected patients with MRI‑visible, biopsy‑confirmed clinically significant prostate cancer (csPCa; e.g., Grade Group 2) and is not appropriate for candidates for active surveillance; suitability depends on tumor volume, location, Gleason score, MRI visibility, and biopsy confirmation.candidate selection criteria

Expert consensus recommends performing FLA within approved clinical trials due to limited validation and follow‑up.

inv-13: Temporary implantable nitinol device (iTind)

iTind shows some durable symptom benefit in selected trial populations but limitations exist.

iTind evidence: Randomized and single‑arm studies report clinically meaningful IPSS improvements and durable outcomes up to 3–4 years in selected populations (typically prostate volume <75 mL), but losses to follow‑up and limited generalizability support cautious adoption and possible limited coverage pending stronger comparative evidence.trial inclusion typically prostate volume <75 mL

RCT vs sham showed mixed primary endpoint results; applicability limited for median lobe pathology and larger prostates.

inv-14: Optilume transurethral drug-coated balloon

Optilume has RCT evidence versus sham with sustained symptom benefit; comparative effectiveness versus standard surgeries is unestablished.

Optilume evidence: A sham‑controlled randomized trial (PINNACLE) demonstrated clinically meaningful and sustained IPSS and Qmax improvements through 1–2 years with preserved sexual function; single‑arm EVEREST data report up to 4‑year follow‑up with sustained benefit. Comparative effectiveness versus established surgical treatments is not available.sham‑controlled RCT demonstrates benefit at 1–2 years

Coverage contingent on meeting trial‑based selection criteria where applicable.

inv-15: Ablation by alternating magnetic field (magnetic nanoparticles)

Magnetic nanoparticle ablation is investigational based on phase I data.

Magnetic nanoparticle ablation: Evidence is limited to a small phase I trial showing feasibility but inconsistent nanoparticle distribution, local discomfort, and some grade‑3 urinary toxicities; insufficient evidence for safety and efficacy to support routine coverage outside clinical trials.phase I data only

Not appropriate for routine coverage.

inv-16: Optilume candidate criteria / evidence summary

Reported trial-based candidate criteria for Optilume to guide selection.

Optilume candidate criteria (reported): Typical inclusion reported in trials: age >50; IPSS ≥13; Qmax 5–15 mL/s with minimum voided volume ≥125 mL; PVR ≤250 mL; prostate volume 20–80 g; prostatic urethral length 35–55 mm; follow‑up and monitoring planned.as listed

Derived from PINNACLE and EVEREST trial eligibility and follow‑up parameters.

inv-17: TULSA candidate criteria / evidence summary

TULSA shows promising short‑term results but limited long‑term comparative data; apply trial exclusions to candidate selection.

TULSA candidate criteria (as reported): Reported inclusion/exclusion from pivotal trials: age 45–80; localized prostate cancer GG1–GG2 in selected trials; PSA ≤15 ng/mL; prostate size limits (≤90 cc; width ≤6 cm, length ≤5 cm); ability to undergo MRI; no implants incompatible with MRI; no tumor within 3 mm of apical plane; no intraprostatic cysts or calcifications >1 cm.as listed

Evidence limited by single‑arm design and short follow‑up; consider use within clinical trials or with documented exclusions reviewed.

inv-18: Transurethral Water Jet Ablation

Aquablation is proven for BPH tissue resection; malignant indications are excluded.

Transurethral water jet ablation (Aquablation): Proven and medically necessary for resection and removal of prostate tissue for treatment of LUTS due to benign prostatic hyperplasia.

Transurethral water jet ablation for the treatment of malignant prostate tissue and all other non‑listed indications is unproven and not medically necessary.

inv-19: Cryoablation

Cryoablation coverage updated to restrict use to recurrent, biopsy‑proven disease.

Cryoablation — policy stance: Cryoablation of the prostate is medically necessary for recurrent prostate cancer diagnosed by biopsy; unproven and not medically necessary for initial treatment of prostate cancer and for all other indications not listed as proven and medically necessary due to insufficient evidence.

Refer to InterQual for clinical criteria when applicable; high‑quality comparative evidence is lacking.

Multiple prostate-directed procedures and indications are explicitly categorized as unproven and not medically necessary when used outside the specific indications listed in this policy. Examples include transurethral ablation when not meeting InterQual-specified clinical criteria, cryoablation for initial treatment of prostate cancer, high-energy water vapor or water jet ablation for malignant prostate tissue, prostate artery embolization for non‑specified uses, and the other device- and focal-therapy procedures listed below that lack sufficient evidence of safety or effectiveness.

High‑energy water vapor thermotherapy (thermal water vapor) has no identified peer‑reviewed original data supporting its use to ablate malignant prostate tissue; therefore, treatment of malignant prostate tissue with high‑energy water vapor thermotherapy is considered unproven and not medically necessary due to insufficient evidence of safety and effectiveness.

Routine use of focal therapy approaches (including focal laser ablation and related focal/interstitial techniques) for clinically localized prostate cancer is not recommended outside prospective clinical trials or well‑designed comparative studies. Published systematic reviews and expert consensus note limited, heterogeneous, and short‑term oncologic outcome data; therefore focal therapies should be restricted to research settings or registries until higher‑quality evidence is available.

Focal therapy (for example focal laser ablation) is not appropriate for patients who are candidates for active surveillance, and should not be used as a routine substitute for established definitive curative therapies. Delphi and systematic‑review guidance emphasize that focal approaches require MRI‑visible, biopsy‑confirmed targets and careful selection; they should not replace standard radical or surveillance strategies outside clinical trials.

TULSA candidacy in published trials excluded individuals with specific anatomic or device‑incompatibility factors; reported exclusion criteria that may render patients ineligible include prostate volume > 90 cc (or width >6 cm or length >5 cm), implants incompatible with MRI, active infection, a tumor within 3 mm of the apical plane on MRI, and intraprostatic cysts or calcifications > 1 cm. These trial‑based limits inform selection and represent circumstances where TULSA would not be appropriate in routine practice.

Transurethral water jet ablation (Aquabeam) is approved and considered proven and medically necessary for resection/removal of prostate tissue to treat LUTS due to benign prostatic hyperplasia. However, use of transurethral water jet ablation to treat malignant prostate tissue and any other indications not explicitly listed in this policy is unproven and not medically necessary because evidence of safety and effectiveness for those uses is lacking.

The following procedures and indications are described in this policy as unproven and not medically necessary due to insufficient evidence of safety or efficacy: transperineal focal laser ablation; insertion of temporary prostatic urethral stents; transperineal laser ablation (TPLA); ablation of malignant prostate tissue by magnetic field induction; transurethral drug‑coated balloon dilation; transurethral thermal ultrasound ablation (TULSA); and transurethral ablation when not meeting InterQual clinical criteria.

Evidence for cryoablation as a primary (initial) treatment for localized prostate cancer is heterogeneous and of limited quality. Systematic reviews summarize mainly single‑arm series and observational studies, with no randomized controlled trials establishing oncologic equivalence to standard curative therapies; therefore the role of cryoablation as an initial definitive therapy remains uncertain.

High‑energy water vapor thermotherapy is supported for BPH indications but lacks peer‑reviewed original data for treatment of malignant prostate tissue. Consequently, high‑energy water vapor thermotherapy of malignant prostate tissue is explicitly considered unproven and not medically necessary in this policy.

Several procedures (for example TPLA and magnetic nanoparticle induction ablation) have inconclusive evidence regarding long‑term safety and effectiveness. Available randomized trials and prospective studies are limited by small sample sizes, single‑center designs, and short follow‑up, preventing reliable assessment of durability and comparative benefit; these procedures are therefore considered investigational outside clinical studies.

Oncologic outcome data for TULSA derive primarily from single‑arm prospective trials with limited follow‑up and no randomized comparators. Although TULSA trials report substantial PSA and prostate volume reductions and acceptable short‑term safety, the evidence is constrained by study design and follow‑up duration, limiting conclusions about long‑term oncologic effectiveness.

Cryoablation is considered medically necessary only for biopsy‑confirmed recurrent prostate cancer as specified in this policy. Use of cryoablation as an initial treatment or for indications not listed as proven is unproven and not medically necessary given limited comparative evidence and heterogeneous outcomes reporting across studies.

Applicable Procedure and Device Codes

Applicable procedure codes (selected)CPT

0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed).
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound.
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL.
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue).
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed.

1–10 of 21

1/3

Device clearance referencesmixed

K193269	UroLift System 510(k) clearance reference
K191505	Rezūm Water Vapor Therapy 510(k) clearance reference
K202961	Aquabeam Robotic System 510(k) clearance reference
P220029A	Optilume Urethral Drug Coated Balloon PMA reference
product codes LLZ, FRN, GEX	Powered laser device product codes for search
product code NOY	Microsphere products search code
product code PLP	High intensity ultrasound ablation systems search code

Common trial thresholds (selection criteria)

IPSSThresholds commonly used in trials: ≥13 (many device trials) or ≥10 in some studies

Qmax (peak urinary flow rate)Typical inclusion range: 5–12 mL/s (some trials use up to 15 mL/s)

Prostate volumeCommon trial range: 20–80 g (some devices restrict to <75 mL or ≤100 cc for specific devices)

Prostatic urethral lengthReported trial inclusion: approximately 32–55 mm (e.g., Optilume/EVEREST)

Post-void residual (PVR)Common maximums reported: ≤250–300 mL in trial eligibility criteria

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Note

Prior authorization may be required for selected prostate procedures and novel devices. Codes marked with an asterisk (*) were not managed for medical necessity review in Indiana as of the policy effective date; always verify the current Indiana prior authorization list at UnitedHealthcare Community Plan of Indiana prior authorization and notification resources.

Check state/contractual requirements and the payer's current prior authorization lists before scheduling.
For novel prostate devices/procedures (e.g., PAE, TPLA, TULSA, drug‑coated balloon systems, transurethral waterjet, Optilume), prior authorization is recommended given variable evidence base and retreatment risks.

Prior Authorization

Prior Authorization Recommended for Newer/Less‑Established Procedures

For newer or less-established procedures, prior authorization is recommended to allow review of clinical indications, selection criteria, and supporting documentation due to limited comparative and long‑term evidence.

Procedures with limited long‑term or comparative data (e.g., PAE, TPLA, TULSA for some indications, transurethral drug‑coated balloon) should be reviewed on a case‑by‑case basis.

Background and Scope

Benign prostatic hyperplasia (BPH) is a common condition in men over age 50 that can cause lower urinary tract symptoms (LUTS) and urinary retention. Management ranges from conservative measures to minimally invasive and surgical interventions. Several device‑based and focal therapies (for example transurethral water jet ablation, transurethral water vapor thermotherapy, prostatic urethral lift, prostate artery embolization, focal laser ablation, and cryoablation) are intended to reduce prostate volume or ablate targeted tissue; evidence for these interventions varies in quality and duration, which informs the policy distinctions between procedures considered proven/medically necessary versus those deemed unproven or investigational.

Definitions and Terms

Cryoablation — definition

DefinitionCryoablation (cryotherapy/cryosurgery) uses transrectal ultrasound-guided probes introduced via the perineum; very cold gas is circulated through probes to freeze and destroy prostate tissue.

Typical clinical useUsed for oncologic ablation of prostate tissue in primary and recurrent prostate cancer contexts; evidence is heterogeneous with mixed outcomes across studies.

Evidence summarySystematic reviews report mostly observational studies and few RCTs, with heterogeneous outcomes and limited high-quality comparative data.

High-energy water vapor thermotherapy (Rezūm) — definition

DefinitionHigh-energy water vapor thermotherapy (Rezūm) uses thermal water vapor delivered into prostatic tissue to reduce prostate volume associated with BPH, including central zone and middle lobe hyperplasia.

Mechanism

Policy Revision History

2026-04-01policy_revisionLatest

Revised coverage rationale: removed guidance on transperineal placement of biodegradable material; clarified cryoablation is medically necessary only for recurrent prostate cancer diagnosed by biopsy and is unproven/not medically necessary for initial treatment and other indications; and clarified transurethral water jet ablation is proven and medically necessary for resection/removal of prostate tissue to treat LUTS due to BPH and unproven/not medically necessary for malignant prostate tissue and other non-listed indications.

2026-04-01policy_update

Added language clarifying medical records documentation expectations for reviews, including that benefit coverage is determined by applicable federal, state, or contractual requirements and that medical records may be required to assess whether the member meets medical necessity.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Indiana Only)

Policy CodePolicy CS334IN.08

Change TypePolicy revision effective 04/01/2026 with material coverage updates

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionInclude legible medical record documentation (history, exam, diagnostics, trial eligibility data) to support medical necessity and prior authorization requests.

SourceLink

On This Page

heterogeneous observational studies

PAE evidence: Systematic reviews and RCTs indicate PAE offers short‑term perioperative benefits but less consistent long‑term functional improvement and higher retreatment rates versus TURP; evidence insufficient for routine replacement of TURP.insufficient long‑term RCT data

Authorization requests should include rationale for selecting the procedure instead of established alternatives.

Prior Authorization

PAE — Prior Authorization Recommended

Prostate artery embolization (PAE) has variable evidence versus TURP and other standards of care; prior authorization is recommended because of evidence variability and notable retreatment rates reported in randomized trials.

Document why PAE is chosen over TURP or other standard surgical options, especially if the patient is a candidate for standard therapies.
Include counseling documenting discussion of higher retreatment likelihood and comparative efficacy.

Prior Authorization

Prior Authorization for Novel Prostate Devices — Provide Trial Eligibility Data

For novel prostate devices and systems (e.g., Optilume BPH Catheter, Aquablation, TULSA), prior authorization requests should include trial eligibility and device‑specific selection data to support appropriateness.

Provide study‑based inclusion criteria that the member meets (e.g., IPSS thresholds, Qmax, prostate volume ranges, absence of obstructive median lobe if required).
For devices with MRI requirements (e.g., TULSA), document MRI compatibility and absence of MRI‑incompatible implants.

Documentation Required

Prior Authorization: Selection Criteria Documentation

When requesting authorization, include documentation that demonstrates the member meets selection criteria derived from guidelines or pivotal trials; absence of such documentation increases the risk of denial.

Document baseline symptom severity and objective measures used in trial inclusion (e.g., IPSS, Qmax, prostate volume).
Document contraindications to or prior failure of guideline‑recommended alternatives, and patient preference if relevant.

Denial Risk

Coverage Risk for Procedures with Insufficient Evidence

Procedures lacking sufficient high‑quality, long‑term comparative evidence are at higher risk for coverage denial. Ensure authorization requests clearly justify medical necessity against established treatments.

PAE and TPLA were noted to have limited long‑term comparative efficacy versus TURP and other standard therapies—highlighting coverage risk.
Requests for therapies considered investigational or with inferior outcomes in randomized trials should include compelling clinical justification.

Denial Risk

Procedures with Insufficient Evidence — Denial Risk

Procedures with insufficient long‑term evidence (for example, TPLA when proposed as standard definitive therapy) may be denied as not medically necessary if documentation does not justify use over established options.

If proposing TPLA as definitive therapy, include reason why TURP or laser enucleation are unsuitable or contraindicated.
If the procedure is primarily being requested to preserve sexual function, document patient counseling and alternative options discussed.

Denial Risk

Exclusion‑Related Denial Risk (TULSA)

TULSA has specific exclusion criteria that, if present, should be documented; failing to document these exclusions or presenting clear exclusion criteria may lead to denial.

Document prostate size and dimensions and confirm they are within device limits (≤ 90 cc, width ≤ 6 cm, length ≤ 5 cm).
Document MRI compatibility, absence of active infection, and absence of tumor within 3 mm of the apical plane when applicable.

Documentation Required

Document Clinical Indications (IPSS, Qmax, Prostate Volume, Sexual Function)

Document baseline clinical indications and objective measures used to assess severity and candidacy for minimally invasive prostate procedures.

Required baseline measures: International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), prostate volume (imaging), and baseline sexual/ejaculatory function (IIEF/MSHQ or equivalent).
Record prior treatments attempted (pharmacotherapy, catheter trials) and reasons for decline or contraindication to standard surgical options.

Documentation Required

Required Clinical Documentation for TULSA Candidacy

For TULSA candidacy and other device‑dependent procedures, include device‑specific clinical documentation: staging, prostate measurements, MRI compatibility, biopsy results, and prior treatment history.

Provide prostate cancer staging (Gleason/Grade Group, clinical stage, PSA) and confirm biopsy results where TULSA is requested for prostate cancer.
Document ability to undergo MRI and absence of MRI‑incompatible implants; include recent MRI report and measurements.
List prior local therapies (radiation, surgery) if TULSA is considered for salvage indications and provide rationale.

Step Therapy

Stepwise Approach Suggested — Prefer Conservative Management First

A stepwise approach is suggested: prefer conservative management and established surgical options before considering novel procedures unless the patient is contraindicated or has failed standard therapies.

Document trials of conservative measures (pharmacologic therapy) and objective response prior to approval of newer interventions.
If conservative or standard surgical therapies were considered but not appropriate, document specific reasons (frailty, comorbidities, patient preference).

Documentation Required

Consideration of Standard Alternatives — Document Step/Alternatives

When considering novel therapies, explicitly document that standard alternatives were considered and discuss alternatives per guideline‑recommended options.

Document that providers discussed and documented alternatives such as PUL, water vapor thermal therapy, TURP, and HoLEP where applicable.
For procedures with specific intended benefits (e.g., preservation of ejaculatory function), document that these outcomes were discussed and informed consent obtained.

Documentation Required

Medical Records and Documentation Requirements

Medical record documentation must fully support medical necessity. Lack of required documentation (history, exam, diagnostics, legibility) may lead to denial or inability to approve services.

Provide legible records of relevant medical history, physical exam, diagnostic test results (IPSS, Qmax, imaging), and informed consent.
Maintain availability of complete records for retrospective review; incomplete documentation increases denial risk.

Thermal energy (steam) causes focal tissue necrosis leading to volume reduction over time.

Indication contextDescribed for treatment of LUTS due to BPH; malignant-tissue treatment lacks peer-reviewed original data and is unsupported.

Transurethral water jet ablation (Aquabeam) — definition

DefinitionTransurethral water jet ablation (Aquabeam) is a robotic, image-guided system that uses a high-velocity, heat-free water jet to resect prostate tissue transurethrally to relieve BPH-related LUTS.

Clinical evidenceRandomized trials (Gilling et al.) comparing aquablation to TURP show similar IPSS and Qmax improvements up to 2–5 years, with potential ejaculatory-function advantages and low retreatment rates in trial follow-up.

ScopeProven and medically necessary for resection/removal of prostate tissue for LUTS due to BPH; use for malignant prostate tissue is unproven and not medically necessary.

Prostatic urethral lift (PUL / UroLift) — definition

DefinitionProstatic urethral lift (PUL, UroLift) places permanent implants to retract lateral (and when applicable median) prostate lobes to reduce urethral obstruction and relieve LUTS.

Indication/limitsFDA-labeled indications and pivotal trials enrolled men generally ≥50 years with IPSS >12 and prostate volumes often in the 30–80 cc range; device intended to preserve sexual function with faster recovery than TURP.

Evidence summaryRandomized sham-controlled and comparative trials show durable symptom improvement up to 5 years but less improvement in peak flow compared with TURP; selection criteria from trials are commonly applied in practice.

Prostate artery embolization (PAE) — definition

DefinitionProstate artery embolization (PAE) is an endovascular radiologic procedure in which microspheres or particles are injected into prostatic arteries to occlude blood flow, causing prostate shrinkage and widening of the urethral lumen.

Clinical roleMay be considered for individuals with BPH who are poor surgical candidates (frailty/comorbidities), have large prostate size in some studies, or have persistent gross hematuria originating from the prostate.

Evidence summarySystematic reviews and RCTs report short-term perioperative benefits (less blood loss, shorter hospitalization) but generally less improvement in long-term functional measures and higher retreatment rates compared with TURP; overall evidence is low–moderate certainty.

Focal laser ablation (FLA) — definition

DefinitionFocal laser ablation (FLA) is a minimally invasive, tumor-directed laser interstitial therapy that applies laser energy to ablate MRI-visible prostate cancer lesions while sparing surrounding glandular tissue.

Intended useProposed as a focal oncologic treatment to preserve urinary and sexual function compared with whole-gland therapies; candidate selection depends on MRI visibility, biopsy confirmation, tumor volume, and grade.

Evidence summaryEvidence is limited to small prospective series and observational studies; systematic reviews report mixed oncologic outcomes and recommend use within clinical trials rather than routine practice.

Prostatic urethral lift (duplicate entry) — definition

DefinitionProstatic urethral lift (PUL, UroLift) places permanent implants to hold open lateral and median lobes of the prostate to improve urinary outflow and relieve LUTS.

Trial-context selectionPivotal trial populations typically included men ≥50 years with IPSS >12, Qmax ≤12 mL/s, and prostate volumes commonly 30–80 cc; outcomes show durable symptom relief up to 5 years.

Coverage stanceProven and medically necessary when performed according to FDA-labeled indications; unproven for other indications.

Prostatic artery embolization (duplicate entry) — definition

DefinitionProstatic artery embolization (PAE) is an endovascular occlusion of prostatic arterial blood flow using microspheres or particles to induce prostate shrinkage and relieve LUTS.

Clinical considerationsEvidence suggests short-term perioperative advantages versus TURP but variable long-term symptom relief; appropriate for selected patients ineligible for standard surgery.

Evidence gapAdditional RCTs with >2 years follow-up are needed to fully evaluate long-term comparative efficacy and retreatment rates relative to TURP and other therapies.

Aquablation — definition

DefinitionAquablation (transurethral waterjet ablation) uses a robotic, image-guided high-velocity waterjet delivered transurethrally to resect benign prostate tissue and relieve LUTS due to BPH.

RCT evidenceRandomized, blinded trials comparing aquablation to TURP demonstrate similar improvements in IPSS and Qmax up to 2–5 years, with possible benefits in ejaculatory preservation and comparable retreatment rates in trial follow-up.

Coverage stanceConsidered proven and medically necessary for resection/removal of prostate tissue to treat LUTS due to BPH; use for malignant tissue is unproven.

Cryoablation (duplicate entry) — definition and mixed evidence

DefinitionCryoablation freezes prostate tissue using transrectal ultrasound-guided probes; it has been used for primary and salvage treatment of prostate cancer.

Evidence characterSystematic reviews report heterogeneous observational studies with inconsistent outcomes; few RCTs exist and overall oncologic equivalence to standard therapies is uncertain.

Policy stanceMedically necessary for recurrent prostate cancer diagnosed by biopsy; unproven and not medically necessary for initial treatment and other non-listed indications.

Prostate artery embolization (duplicate) — radiologic endovascular procedure

DefinitionProstate artery embolization (PAE) is a radiologic endovascular procedure that embolizes prostatic arteries using particles to reduce prostate volume and relieve lower urinary tract symptoms.

Procedural settingPerformed by interventional radiology teams; involves arterial access and catheter-directed particle delivery into prostatic arterial branches.

Comparative outcomesTrials and reviews note reduced perioperative morbidity but less consistent long-term symptomatic and functional improvement versus TURP, and higher retreatment rates in some studies.

Transperineal focal laser ablation (TPLA/FLA) — definition

DefinitionTransperineal focal laser ablation (TPLA/FLA) delivers laser energy via a transperineal approach to target MRI-visible prostate cancer lesions while sparing surrounding tissue.

Candidate selectionReported series and trials enrolled men with MRI-visible, biopsy-confirmed localized disease (often ISUP grade ≤2) and excluded multifocal or large lesions; re-biopsy and imaging follow-up commonly used to assess efficacy.

Evidence and recommendationExisting evidence is limited and conflicting; expert consensus and systematic reviews recommend restricting routine use to clinical trials or prospective studies due to limited oncologic validation.

Clinically significant prostate cancer (csPCa) definition

DefinitionClinically significant prostate cancer (csPCa) is defined by the referenced Delphi consensus as any volume Grade Group 2 (Gleason score 3 + 4).

Role in focal therapyThis csPCa definition is used to identify index lesions appropriate for consideration of focal ablative approaches in expert consensus statements.

ImplicationPatients with csPCa may be considered for focal therapies in trials, but candidates for active surveillance are generally not appropriate for focal ablation.

Eligibility thresholds commonly used in trials

AgeTrials commonly include men aged ≥50 years (some devices/trials specify 45+ for certain procedures)

IPSSTypical inclusion: IPSS ≥10 or ≥13 depending on the study/device; many pivotal studies use ≥13

Flow and volume limitsQmax often ≤12–15 mL/s; prostate volume commonly 20–80 g (some devices restrict to <75 mL or ≤100 cc); PVR limits commonly ≤250–300 mL

Optilume BPH Catheter System — definition

DefinitionOptilume BPH Catheter System is a transurethral drug-coated balloon that combines mechanical dilation with an antiproliferative drug coating (paclitaxel) to maintain prostatic urethral patency after dilation.

Trial inclusionPivotal trials (PINNACLE, EVEREST) enrolled men ≥50 with IPSS ≥13, Qmax typically 5–15 mL/s, prostate volume 20–80 g, prostatic urethra length ~35–55 mm, and PVR limits (≤250–300 mL) with specific minimum voided volume requirements.

Evidence summaryRandomized sham-controlled and single-arm studies show clinically meaningful improvements in IPSS and Qmax through 1–4 years, but comparative effectiveness versus established surgical treatments is not established.

TULSA — definition

DefinitionTULSA (Transurethral Thermal Ultrasound Ablation) is an MRI-guided transurethral ultrasound ablation technique that delivers thermal energy to ablate prostate tissue for whole- or partial-gland treatment of localized prostate cancer.

Trial eligibility/exclusionsPivotal trials (TACT) enrolled men aged 45–80 with GG1–GG2 disease, PSA ≤15 ng/mL, prostate size limits (≤90 cc; width ≤6 cm; length ≤5 cm), ability to undergo MRI; exclusions included implants incompatible with MRI, active infection, tumor within 3 mm of apical plane, and large intraprostatic cysts/calcifications (>1 cm).

Evidence summarySingle-arm prospective data show PSA and volume reductions and acceptable short-term safety at 12 months, but lack comparative trials and longer-term oncologic outcomes for routine adoption.

Moderate-to-severe LUTS / BPO interventions per EAU 2023

EAU 2023 summaryEAU 2023 recommends surgical treatment options stratified by prostate size and anatomy, including TURP, HoLEP, open prostatectomy, and lists PUL and Aquablation as options in selected prostate-size ranges.

PUL recommendationProstatic urethral lift (UroLift) is recommended for men with prostates <70 mL without a middle lobe who wish to preserve ejaculatory function.

Aquablation recommendationAquablation is an alternative to TURP for patients with moderate-to-severe LUTS and prostate volume 30–80 mL.